# A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males

> **NCT07630233** · PHASE1 · RECRUITING · sponsor: **The United Bio-Technology (Hengqin) Co., Ltd.** · enrollment: 53 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** UBT38006
- **DRUG:** Placebo
- **DRUG:** Insulin Degludec Injection
- **DRUG:** Insulin Icodec Injection

## Key facts

- **NCT ID:** NCT07630233
- **Lead sponsor:** The United Bio-Technology (Hengqin) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-17
- **Primary completion:** 2026-10-25
- **Final completion:** 2026-10-25
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2026-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07630233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07630233, "A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07630233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*